BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

GlobalData Release: Arthritis Drug Disappointment: Will Fostamatinib's Failure Force Pharma Back to the Drawing Board?


6/7/2013 10:19:51 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

LONDON, UK (GlobalData), 7 June 2013 - Recent news of fostamatinib’s latest failure to meet clinical endpoints marks yet another blow to an already weakened rheumatoid arthritis (RA) therapeutics pipeline, and may drive manufacturers to investigate fresh approaches to drug development, says an analyst with research and consulting firm GlobalData. This latest disappointment marks the official demise of AstraZeneca (AZ) and Rigel Pharmaceuticals’ (Rigel) troubled Phase III program for fostamatinib (entitled OSKIRA), and comes not long after Eli Lilly’s shelving of its RA candidate, tabalumab, in February.

“These recent events clearly show that the path to regulatory approval in RA remains a challenging one for both novel small molecules and biologics,” says Dina Rufo, immunology analyst with GlobalData.

“Considering these setbacks in the RA pipeline, we believe companies with RA therapies in early development are likely to be watching closely, and may need to reconsider their own clinical development programs in hope that they can bring their drugs to the market.”

With the latest competitors out of the picture, Pfizer’s approval of Xeljanz (tofacitinib) in the US (November 2012) and Japan (March 2013) appears even more significant. However, Pfizer’s product has not been without its own share of problems:

“Xeljanz has faced other obstacles,” states Rufo, “including a somewhat surprising negative ruling for its application for RA by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP), which Pfizer is likely to fight against over the coming months.

“As such, we believe that the CHMP’s decision will have a negative impact on Xeljanz’s development in other autoimmune indications, such as psoriasis and ulcerative colitis, with potentially limited early uptake,” adds GlobalData’s analyst.



Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES